Autolus (AUTL) Q3 2026 Earnings Call Transcript

Autolus Therapeutics reported 95% year-over-year revenue growth in the third quarter and raised its 2026 revenue guidance to at least $150 million. Gross margin reached 57%, marking a third consecutive quarter of positive gross margins. Management said it is delaying key autoimmune pipeline data to allow longer follow-up, while cash reserves and expected product sales are projected to fund operations into early 2028.